Log in to search using one of your social media accounts:

 

Cancer Doctors Cite Risks of Drinking Alcohol
Drinking alcohol, even modest amounts, increases the risk of breast cancer and other cancers. (Source: NYT Health)
Source: NYT Health - November 7, 2017 Category: Consumer Health News Authors: RONI CARYN RABIN Tags: Head and Neck Cancer Breast Cancer Esophageal Cancer Mouth Colon and Colorectal Cancer Liver Cancer Alcoholic Beverages Alcohol Abuse Advertising and Marketing Source Type: news

“Bubbles” Boost Search for Treatment to Aid Head and Neck Cancer Patients
A scientific team at the University of Rochester is using innovative technology to discover preventative treatments for salivary gland radiation damage typical for head and neck cancer patients —and recently received a $3.8 million National Institutes of Health grant to support their investigation. (Source: University of Rochester Medical Center Press Releases)
Source: University of Rochester Medical Center Press Releases - October 26, 2017 Category: Universities & Medical Training Authors: University of Rochester Medical Center Source Type: news

Proton therapy lowers treatment side effects in pediatric head and neck cancer patients
(University of Pennsylvania School of Medicine) Pediatric patients with head and neck cancer can be treated with proton beam therapy (PBT) instead of traditional photon radiation, and it will result in similar outcomes with less impact on quality of life. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 23, 2017 Category: Cancer & Oncology Source Type: news

Medical News Today: Head and neck cancer: Could oral sex raise your risk?
Researchers have found a link between oral sex and smoking and an increased risk of a type head and neck cancer triggered by the human papillomavirus. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 21, 2017 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

Oral Sex Plus Smoking a Cancer Danger for Men
Risk of head and neck tumors tied to HPV infection jumps to 15 percent for this group, study finds (Source: WebMD Health)
Source: WebMD Health - October 20, 2017 Category: Consumer Health News Source Type: news

Men who perform oral sex on women 'more at risk of mouth and throat cancers'
Conclusion This study uses a large amount of national data to give us an idea about which groups of people have the greatest risk of carrying potentially cancer-causing oral HPV . But while oral HPV may increase people's risk of mouth and throat cancers, the actual number who would go on to develop cancer is extremely small. This study has limitations, which are worth bearing in mind: It only looked at whether people had oral HPV at a single point in time. This makes it difficult to know at what point they became infected and how much this could be down to other risk factors such as smoking, oral sex and number of partne...
Source: NHS News Feed - October 20, 2017 Category: Consumer Health News Tags: Cancer Source Type: news

Oral Sex Plus Smoking a Cancer Danger for Men
Risk of head and neck tumors tied to HPV infection jumps to 15 percent for this group, study findsSource: HealthDay Related MedlinePlus Pages: HPV, Men's Health, Smoking (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - October 20, 2017 Category: Consumer Health News Source Type: news

Oral Sex Plus Smoking a Cancer Danger for Men
FRIDAY, Oct. 20, 2017 -- Smoking and oral sex may be a deadly combo that raises a man's risk for head and neck cancer, a new study suggests. The key factor is transmission of oral strains of the cancer-linked human papillomavirus (HPV), which can... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - October 20, 2017 Category: General Medicine Source Type: news

Oral Sex Plus Smoking a Cancer Danger for Men
Risk of head and neck tumors tied to HPV infection jumps to 15 percent for this group, study finds (Source: Cancercompass News: Gynecological Cancer)
Source: Cancercompass News: Gynecological Cancer - October 20, 2017 Category: Cancer & Oncology Source Type: news

Varian launches Halcyon treatment in EU
Varian Medical (NYSE:VAR) said today it launched its Halcyon image-guided volumetric intensity modulated radiotherapy cancer treatment system in the European Union, with the 1st patient being treated in Blegium. The Palo Alto, Calif.-based company said its Halcyon IMRT system features improvements that make it more comfortable for patients and streamline operator’s workflow, only requiring 9 steps from start to treatment, down from 30 steps in legacy machines. Varian said the device is designed to handle “the majority” of cancer patients, including individuals with prostate, breast, head & neck and ot...
Source: Mass Device - October 19, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Oncology Varian Medical Systems Source Type: news

7 Million American Men Carry Cancer-Causing HPV
The incidence of mouth and throat cancers caused by the human papillomavirus in men has now surpassed the incidence of HPV-related cervical cancers in women. (Source: NYT Health)
Source: NYT Health - October 18, 2017 Category: Consumer Health News Authors: NICHOLAS BAKALAR Tags: Head and Neck Cancer Human Papillomavirus (HPV) Sexually Transmitted Diseases Throat Smoking and Tobacco Men and Boys Vaccination and Immunization Infections Source Type: news

HPV causing cancer of head, neck affects more men than women in U.S.
A U.S. study suggests that 1 in 9 men has an oral HPV infection. HPV-related head and neck cancers are on the rise. (Source: CBC | Health)
Source: CBC | Health - October 17, 2017 Category: Consumer Health News Tags: News/Health Source Type: news

7 Million American Men Carry Cancer-Causing HPV Virus
The incidence of mouth and throat cancers caused by the human papilloma virus in men has now surpassed the incidence of HPV-related cervical cancers in women. (Source: NYT Health)
Source: NYT Health - October 16, 2017 Category: Consumer Health News Authors: NICHOLAS BAKALAR Tags: Head and Neck Cancer Human Papillomavirus (HPV) Sexually Transmitted Diseases Throat Smoking and Tobacco Men and Boys Vaccination and Immunization Infections Source Type: news

In global first, Penn using glowing tumor dye to identify cancerous lymph nodes
(University of Pennsylvania School of Medicine) Surgeons at Penn Medicine are using a fluorescent dye that makes cancerous cells glow in hopes of identifying suspicious lymph nodes during head and neck cancer procedures. Led by Jason G. Newman, MD, FACS, an associate professor of Otorhinolaryngology in the Perelman School of Medicine at the University of Pennsylvania, the study is the first in the world to look at the effectiveness of intraoperative molecular imaging (IMI) of lymph nodes in patients with head and neck cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 10, 2017 Category: International Medicine & Public Health Source Type: news

7 medtech stories we missed this week: Sept. 29, 2017
[Image from unsplash.com]From EOI getting FDA clearance to Sanuwave’s new joint venture agreement, here are seven medtech stories we missed this week but thought were still worth mentioning. 1. EOI wins FDA nod for FLXfit15 expandable cage EOI announced in a Sept. 28 press release that it has received FDA 510(k) clearance for its FLXfit 15. The clearance will help enhance the company’s FLXfir 3D expandable cage system and help expand the surgeon’s flexibility and capability by offering different length options. 2. ivWatch inks distribution deal with Terumo ivWatch has recently signed a licensing...
Source: Mass Device - September 29, 2017 Category: Medical Devices Authors: Danielle Kirsh Tags: Business/Financial News Clinical Trials Diagnostics Food & Drug Administration (FDA) Cefaly EOI ivwatch Lombard Medical MedTech Mortise Medical Mundimed Sanuwave Terumo Varian Medical Systems Source Type: news

Drug combination may improve impact of immunotherapy in head and neck cancer
(University of California - San Diego) Checkpoint inhibitor-based immunotherapy has been shown to be very effective in recurrent and metastatic head and neck cancer but only in a minority of patients. University of California San Diego School of Medicine researchers may have found a way to double down on immunotherapy's effectiveness. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 21, 2017 Category: International Medicine & Public Health Source Type: news

Short dental implants: A scoping review of the literature for patients with head and neck cancer
ConclusionsShort dental implants (6 mm to 8 mm) can be used successfully to support single or multiple fixed reconstructions or overdentures in atrophic maxillae and mandibles. The use of short dental implants lessens the need for advanced and complicated surgical bone augmentation procedures, which reduces complications, costs, treatment time, and morbidity. Short implants could be an alternative in the rehabilitation of patients with cancer. (Source: Dental Technology Blog)
Source: Dental Technology Blog - September 20, 2017 Category: Dentistry Source Type: news

Tailored Treatment for Head-and-Neck Cancer Mystery
Treatment TermsHead and Neck Cancer Overview Rob Vaughn found a lump on his neck that turned out to be cancer that had spread from somewhere else in his body. The trouble was, doctors couldn ’t find the original site of the cancer. That made his treatment decisions difficult -- until two Duke specialists offered him options, including the option for watchful waiting instead of extensive treatment. Hero Image20170914_robvaughn_neckcancer_083_herocrop.jpg Preview Image Content Blocks Header A Search for the Source of Cancer ContentVaughn, a Charlotte, NC, father of two, was 47 and in good health when he felt th...
Source: dukehealth.org: Duke Health News - September 15, 2017 Category: Consumer Health News Authors: mf205 at duke.edu Source Type: news

Tactile Medical shareholders ready $109 million offering
Tactile Systems Technology said this week that its investors have priced a new offering, looking to raise approximately $109 million. In the offering, investors in the Minneapolis, Minn.-based company will look to offer 3.3 million shares of common stock at approximately $33 per share. The offering will also include an underwriters option to purchase an additional 495,000 shares, which could bring in an additional $16.3 million. Tactile said it will receive no proceeds from the offering, which is expected to close today. William Blair & Co. and Piper Jaffray & Co. are acting as joint book runners, with Cannaco...
Source: Mass Device - September 15, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Tactile Systems Technology Source Type: news

Monopar receives licence to develop Onxeo ’s Validive oral mucositis treatment
Onxeo has granted a global exclusive licence to Monopar Therapeutics for its Validive (clonidine mucoadhesive buccal) tablet used to treat severe oral mucositis induced by radiotherapy or chemotherapy in patients suffering from head and neck cancer. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - September 13, 2017 Category: Pharmaceuticals Source Type: news

Cancer drug stimulates tripolar mode of mitosis
(Helmholtz Zentrum M ü nchen - German Research Center for Environmental Health) Taxanes inhibit cell division and make cancer cells sensitive to radiation therapy. A current study has investigated the underlying mechanisms of this action - and which biomarkers may be useful for predicting the success of therapy. The study, published in the journal Oncogene, was carried out within the framework of the Clinical Cooperation Group Personalized Radiotherapy in Head and Neck Cancer at Helmholtz Zentrum M ü nchen and Munich University Hospital. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - September 12, 2017 Category: Biology Source Type: news

KEYNOTE-040 evaluates pembrolizumab in head and neck cancer
(European Society for Medical Oncology) Immunotherapy with the checkpoint inhibitor pembrolizumab may be a better option than standard treatments for patients whose head and neck cancer has spread, or recurred after an initial round of chemotherapy, according to results of the Keynote-040 trial presented at the ESMO 2017 Congress in Madrid. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 11, 2017 Category: Cancer & Oncology Source Type: news

World Trade Center responders might face greater risk of HPV throat and tongue cancer
(Rutgers University) Researchers at Rutgers University -- investigating the causes of head and neck cancers in World Trade Center rescue and recovery workers -- will take the lead in a study to determine whether the responders are at a greater risk for human papillomavirus (HPV)-related throat and tongue cancer because of their exposure to toxic dust and debris. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 8, 2017 Category: International Medicine & Public Health Source Type: news

From bed to bench and back to bed: Mimicking how HPV-positive cancer responds to treatment
(Medical University of South Carolina) Patients with head and neck cancer who are also positive for human papilloma virus (HPV) are known to have a better prognosis compared to patients with HPV-negative disease, independent of therapeutic intervention. Researchers at the Medical University of South Carolina Hollings Cancer Center have discovered one reason why and have identified a peptide that, in preclinical studies, can act on the identified mechanism to improve outcomes in HPV-negative head and neck cancer. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - September 7, 2017 Category: Biology Source Type: news

Oral Sex Plus Smoking a Cancer Danger for Men
Risk of head and neck tumors tied to HPV infection jumps to 15 percent for this group, study finds (Source: Fertility News - Doctors Lounge)
Source: Fertility News - Doctors Lounge - September 1, 2017 Category: Reproduction Medicine Tags: Infections, Oncology, Reproductive Medicine, Preventive Medicine, News, Source Type: news

Physician experts highlight research ahead of Otolaryngology's annual meeting
(American Academy of Otolaryngology - Head and Neck Surgery) The latest research on patient preferences, quality-of-life, ear health, thyroidectomy, and other topics related to the specialty of otolaryngology will be presented in Chicago, IL, Sept. 10-13, during the AAO-HNSF 2017 Annual Meeting& OTO Experience. The 2017 Annual Meeting includes hundreds of research presentations. All abstracts to be presented are now available online. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 1, 2017 Category: Cancer & Oncology Source Type: news

After Skull Base Tumor, Dancer/Model Takes on Law School
Treatment TermsSkull base tumor Author Karen Doss Bowman Overview Victoria Vesce had surgery and 28 rounds of radiation for rare tumors in the base of her skull and in her neck. Four days after her last radiation treatment, she started law school. Hero Image20170809.vesce_.victoria.03.blog_.jpg Preview Image Content Blocks Section Header Image/Videovesce_honeybee_blog.jpg Section Features Images/Media Text Content Section Header Image/Videovesce_blog_secondary3.jpg Section Features Images/Media Text Content Header A Regional Destination for Rare Head and Neck Tumors ContentPatients from throughout the Sou...
Source: dukehealth.org: Duke Health News - August 23, 2017 Category: Consumer Health News Authors: mf205 at duke.edu Source Type: news

Cel-Sci raises $3.5m for head and neck cancer immunotherapy
Cel-Sci (NYSE:CVM) said today that it inked an agreement with institutional investors for a $3.5 million registered direct offering. The company said it plans to offer 1.75 million shares of common stock at $2.00 apiece. In a private placement, Cel-Sci will issue warrants to buy up to 1.75 million shares of common stock. For each share of stock purchased in the registered direct offering, investors in the private placement will receive an unregistered warrant to buy one share of common stock, which have an exercise price of $2.30 apiece. Get the full story at our sister site, Drug Delivery Business News...
Source: Mass Device - August 23, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Funding Roundup Oncology Pharmaceuticals Wall Street Beat cel-sci Source Type: news

Nutlin-3, a p53-Mdm2 antagonist for nasopharyngeal carcinoma treatment
(Bentham Science Publishers) Nasopharyngeal carcinoma (NPC) is a form of head and neck cancer that is highly prevalent among men in the populations of Southern China and Southeast Asia. This review will discuss the potential use of Nutlin-3 as a p53-activating drug and the future directions of its clinical research for NPC treatment. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 23, 2017 Category: Cancer & Oncology Source Type: news

Study provides insight into link between two rare tumor syndromes
FINDINGSUCLA researchers have discovered that timing is everything when it comes to preventing a specific gene mutation in mice from developing rare and fast-growing cancerous tumors, which also affects young children. This mutation can also cause a benign tumor condition in humans in adulthood.The scientists found that when one tumor suppressor gene is turned off or inactivated during early stages of a developing mouse embryo, it induces the formation of a malignant tumor. The research demonstrates that this type of malignant tumor will not form if the gene is inactivated during later stages of nerve development. However,...
Source: UCLA Newsroom: Health Sciences - August 21, 2017 Category: Universities & Medical Training Source Type: news

FDA lifts hold on Cel-Sci's clinical trial for head and neck cancer drug
The U.S. Food and Drug Administration lifted a partial hold it placed nearly a year ago on a clinical trial for a head and neck cancer drug from Vienna-based Cel-Sci Corp. The company announced Monday morning it has received the go-ahead to resume the phase 3 clinical trial of immunotherapy drug Multikine. Cel-Sci had brought on 926 patients out of a desired 1,273 when the hold was put in place in September. The FDA instituted the hold because of an unreasonable an d significant risk of illness… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - August 14, 2017 Category: American Health Authors: Drew Hansen Source Type: news

Prevention of HPV-Related Oral Cancer by Dentists: Assessing the Opinion of Dutch Dental Students
Journal of Cancer Education pp 1 –8AbstractThe aim of this study is to assess dental students ’ opinions of the dentists’ role in primary prevention of human papillomavirus (HPV)-related oral cancer using a cross-sectional web-based survey. A questionnaire, containing questions about knowledge of HPV and oral cancer, confidence in head and neck examination and role of the dentist in preventing HPV-related oral cancer, was sent to all students of the Academic Centre of Dentistry Amsterdam (n = 912). One hundred and twenty-six (n = 126) students completed the questionnaire. Significantly...
Source: Dental Technology Blog - August 2, 2017 Category: Dentistry Source Type: news

Adherence to Quality Metrics Could Improve Head and Neck Cancer Survival
Adherence to each of five quality metrics for head and neck squamous cell carcinoma was associated with a reduced risk for death. (Source: CancerNetwork)
Source: CancerNetwork - July 31, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Head & Neck Cancer News Source Type: news

Merck immunotherapy fails to improve survival in head and neck cancer
(Reuters) - Merck& Co said on Monday that its Keytruda immunotherapy failed to extend survival in previously treated patients with advanced head and neck cancer more than the standard combination therapy in a late-stage trial. (Source: Reuters: Health)
Source: Reuters: Health - July 24, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

New Data Show TomoTherapy(R) System Superior to RapidArc in Achieving Local Control of Head and Neck Cancers
Prospective, Multicenter Study Supported by the French National Institute of Cancer Also Demonstrates that Treatment with the TomoTherapy Platform Resulted in a Significantly Better Cancer-Specific Survival Rate and Post-Treatment Salivary Function SUNN... Devices, Oncology Accuray, TomoTherapy, radiosurgery, radiotherapy, RapidArc (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 20, 2017 Category: Pharmaceuticals Source Type: news

Accuray touts study data in head-to-head between TomoTherapy and Varian ’ s RapidArc
Accuray (NSDQ:ARAY) today released data from a prospective study comparing its TomoTherapy intensity-modulated radiation therapy system with Varian Medical‘s (NYSE:VAR), RapidArc radiotherapy system, touting a higher survival rate for patients treated with its TomoTherapy system. Results from the study were published last month in the International Journal of Radiation Oncology – Biology – Physics. Accuray said that the 166-patient, multi-center study was the 1st to prospectively compare clinical outcomes across radiation platforms. In the study, 74 individuals were treated with the TomoTherapy...
Source: Mass Device - July 20, 2017 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Oncology Accuray Inc. Varian Medical Systems Source Type: news

7 medtech stories we missed this week: July 14, 2017
[Image from unsplash.com]From Novarad touting its VR-surgical guidance system to Zynex paying off its $2.2M loan, here are seven medtech stories we missed this week but thought were still worth mentioning. 1. Stimwave announces first patient in Brazil Stimwave announced in a July 5 press release that its first patients in Brazil have received Stimwave’s wireless pain relief device treatment for chronic pain. The patients are expected to receive the neuromodulation treatment as an alternative to opioid pain relief. The devices created by Stimwave deliver small pulses of energy to specific nerves to trigger a reac...
Source: Mass Device - July 14, 2017 Category: Medical Devices Authors: Danielle Kirsh Tags: Clinical Trials Diabetes Diagnostics Imaging Neuromodulation/Neurostimulation Pain Management Research & Development American Red Cross Nemaura Medical Novarad Owlstone Medical Stimwave Tactical Medical Zynex Inc. Source Type: news

Mesothelioma Clinical Trial Combines Immunotherapy Drugs
Dr. Tawee Tanvetyanon at the Moffitt Cancer Center in Tampa rarely sounds this enthused about the future prospects for patients with pleural mesothelioma. Finally, he has something promising to offer. Tanvetyanon is the principal investigator of a much-anticipated phase II clinical trial involving an immunotherapy drug combination with considerable potential for extending survival. “This is exciting. We now can offer something with realistic hope,” he told Asbestos.com. “We haven’t had anything like this for mesothelioma in a long time. I really look forward to speaking with these patients now.&rdqu...
Source: Asbestos and Mesothelioma News - July 13, 2017 Category: Environmental Health Authors: Matt Mauney Tags: Abramson Cancer Center Aduro Biotech CRS-207 Dr. Tawee Tanvetyanon FDA approval Keytruda improving mesothelioma prognosis Merck mesothelioma chemotherapy mesothelioma clinical trials mesothelioma immunotherapy moffitt cancer center m Source Type: news

Three-Weekly Cisplatin Superior to Weekly Dose in Head and Neck Cancer
Three-weekly cisplatin is superior to a weekly dose in preventing locoregional relapse when combined with radiotherapy in head and neck squamous cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - July 3, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Head & Neck Cancer News Source Type: news

NIDCR Science News
Having trouble viewing this email? View it as a Web page. Delivering a One-Two Punch to Head and Neck CancerUniversity of California, Los Angeles • June 27, 2017 Blocking Yeast-Bacteria Interaction May Prevent Severe Biofilms that Cause Childhood Tooth Decay University of Pennsylvania • June 20, 2017 Sugar-coated Nanomaterial Excels at Promoting Bone Growth Northwestern University • June 19, 2017 Artificial Cartilage Under Tension as Strong as Natural University of California Davis &bu...
Source: NIDCR Science News - June 30, 2017 Category: Dentistry Source Type: news

Nivolumab Maintained QOL in Advanced Squamous Cell Head and Neck Cancer
Patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with the checkpoint inhibitor nivolumab were able to maintain baseline levels of quality of life. (Source: CancerNetwork)
Source: CancerNetwork - June 28, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Head & Neck Cancer News Source Type: news

Reduced Cancer - Independent Life Expectancy in Head, Neck Cancer
Cancer - independent life expectancy 6.5 years shorter for patients with head and neck cancer (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 27, 2017 Category: Cancer & Oncology Tags: Cardiology, Family Medicine, Internal Medicine, Nursing, Oncology, ENT, Pathology, Pulmonology, Radiology, Surgery, Journal, Source Type: news

Head and neck cancer cured with THIS treatment: Swollen glands were only symptoms
HEAD and neck cancers include cancers of the nose, mouth and throat and there are more than 10,000 cases diagnosed in the UK every year. (Source: Daily Express - Health)
Source: Daily Express - Health - June 24, 2017 Category: Consumer Health News Source Type: news

Immunotherapy kinder than chemotherapy for patients with head and neck cancer
(Institute of Cancer Research) The immunotherapy nivolumab is kinder than chemotherapy for people with advanced head and neck cancer -- easing many of the negative effects of the disease on patients' quality of life. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 23, 2017 Category: International Medicine & Public Health Source Type: news

Neoadjuvant Pembrolizumab Promising in Head and Neck Cancer Neoadjuvant Pembrolizumab Promising in Head and Neck Cancer
The data are early and the cohort small, but use in the neoadjuvant and adjuvant setting showed antitumor activity.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 21, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Treatment of Head and Neck Paragangliomas Treatment of Head and Neck Paragangliomas
Is first-line treatment for carotid body tumors the same as that for jugular and vagal paragangliomas?Cancer Control: Journal of the Moffitt Cancer Center (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 20, 2017 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Galera enrols last patient in Phase IIb trial of GC4419 to treat oral mucositis
US-based biotechnology company Galera Therapeutics has concluded enrolment in the Phase IIb clinical trial of GC4419 for the treatment of oral mucositis (OM) in patients with head and neck cancer. (Source: Drug Development Technology)
Source: Drug Development Technology - June 18, 2017 Category: Pharmaceuticals Source Type: news

New UPMC Hillman Cancer Center leader named
UPMC Hillman Cancer Center has named Dr. Robert L. Ferris as its new director, effective July 1. Ferris, who has worked for the Hillman Cancer Center for 15 years, is a nationally known immunotherapy expert. He will replace Dr. Nancy Davidson, who left last year for a job in Washington State. Ferris is chief of UPMC's Division of Head and Neck Oncologic Surgery, co-leader of the Cancer Immun ology Program and associate director for translational research/co-director of the Tumor Microenvironment… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - June 16, 2017 Category: Pharmaceuticals Authors: Paul J. Gough Source Type: news

Tumor PD-L2 expression may predict patient response to anti-PD-1 immunotherapy
(American Association for Cancer Research) PD-L2 protein expression in human tumors was associated with clinical response to pembrolizumab (Keytruda), an anti-PD-1 immunotherapy, independent of PD-L1 expression, in patients with head and neck squamous cell carcinoma (HNSCC). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 15, 2017 Category: International Medicine & Public Health Source Type: news

HPV Vaccination Prevents Cancers in Men, Too
For years, scientists have touted the HPV vaccination ’s power to reduce cervical cancer in women. Now, during Men’s Health Week, Texas physicians urge men to get vaccinated against HPV to prevent cancers. HPV causes several cancers in men and women, including oropharyngeal (cancers of the head and neck such as the throat and mouth), penile, anal, cervical and vaginal. Some cases are fatal. (Source: TMA News Room)
Source: TMA News Room - June 14, 2017 Category: Consumer Health News Source Type: news